Lipella rises after completing dosing of patient group in drug trial

Lipella Pharmaceuticals

22/11/2024 13:51

** Lipella Pharmaceuticals'  LIPO.O  shares rise 7% to $2.59
premarket
    ** LIPO says completed dosing of first group of patients in
mid-stage study of LP-310, its key experimental drug to treat
oral lichen planus
    ** OLP is a chronic inflammatory disease that affects mucous
membranes inside the mouth
    ** Disease affects about 6-7 million Americans, and has no
approved drug besides those used to alleviate symptoms, the co's
website says 
    ** As of last close, stock had fallen 70% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com;))